Literature DB >> 8231842

Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS).

G F Watts1, S Mandalia, J N Brunt, B M Slavin, D J Coltart, B Lewis.   

Abstract

Associations between plasma lipoprotein subfractions and changes in coronary artery diseases (CAD) were examined in 74 men who completed the St. Thomas' Atherosclerosis Regression Study (STARS). Plasma lipoproteins were isolated by stepwise, preparative ultracentrifugation at repeated intervals during the 38-month trial. Paired coronary angiograms were quantitatively analyzed by a computerized method. In univariate linear regression analysis, changes in mean absolute width (delta MAWS) and minimum absolute with (delta MinAWS) of coronary segments were significantly correlated with in-trial concentrations of cholesterol in intermediate-density lipoprotein ([IDL] d = 1.006 to 1.019 kg/L), low-density lipoprotein ([LDL2] d = 1.019 to 1.040 kg/L; LDL3, d = 1.040 to 1.063 kg/L), and high-density lipoprotein ([HDL3] d = 1.125 to 1.210 kg/L) subfractions; no significant associations were found with other lipoproteins. IDL, LDL3, and HDL3 cholesterol were then selected for multiple linear regression analysis because these variables were not co-correlated and because they attained a significance of P less than or equal to .1 in univariate regression. In this analysis, only LDL3 cholesterol level was a significant negative predictor (P < .05) of both delta MAWS and delta MinAWS; a positive association between delta MinAWS and HDL3 cholesterol level just failed to reach conventional statistical significance (P = .066). Correlations between changes in coronary luminal dimensions and LDL3 cholesterol level were independent of age, smoking, weight, and blood pressure. Most patients showing regression of coronary atherosclerosis had an LDL3 cholesterol level of less than 1.8 mmol/L. The findings suggest that LDL3 is the plasma lipoprotein subfraction that exerts the single most powerful effect on the course of CAD in middle-aged men with hypercholesterolemia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8231842     DOI: 10.1016/0026-0495(93)90199-x

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  30 in total

1.  Small, dense, low-density lipoprotein and atherosclerosis.

Authors:  H R Superko
Journal:  Curr Atheroscler Rep       Date:  2000-05       Impact factor: 5.113

2.  Apolipoprotein B versus lipoprotein lipids: vital lessons from the AFCAPS/TexCAPS trial.

Authors:  A D Sniderman; J Bergeron; J Frohlich
Journal:  CMAJ       Date:  2001-01-09       Impact factor: 8.262

3.  Hypercholesterolemia and Dyslipidemia.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-04

Review 4.  Reduced or modified dietary fat for preventing cardiovascular disease.

Authors:  Lee Hooper; Carolyn D Summerbell; Rachel Thompson; Deirdre Sills; Felicia G Roberts; Helen J Moore; George Davey Smith
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

Review 5.  Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy.

Authors:  Richard J Woodman; Gerard T Chew; Gerald F Watts
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 6.  Is it LDL particle size or number that correlates with risk for cardiovascular disease?

Authors:  H Robert Superko; Radhika R Gadesam
Journal:  Curr Atheroscler Rep       Date:  2008-10       Impact factor: 5.113

Review 7.  Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.

Authors:  J P Desager; Y Horsmans
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

Review 8.  Postprandial hypertriglyceridemia and cardiovascular disease: current and future therapies.

Authors:  D C Chan; J Pang; G Romic; G F Watts
Journal:  Curr Atheroscler Rep       Date:  2013-03       Impact factor: 5.113

9.  Hypercholesterolemia and Dyslipidemia: Issues for the Clinician.

Authors:  H. Robert Superko; Nicolas A. Chronos
Journal:  Curr Treat Options Cardiovasc Med       Date:  2003-02

10.  Significance of small dense low-density lipoprotein as a risk factor for coronary artery disease and acute coronary syndrome.

Authors:  Sung Woo Kwon; Se-Jung Yoon; Tae Soo Kang; Hyuck Moon Kwon; Jeong-Ho Kim; Jihyuk Rhee; Sung-Ju Lee; Jong-Kwan Park; Jae Yun Lim; Young Won Yoon; Bum Kee Hong
Journal:  Yonsei Med J       Date:  2006-06-30       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.